112 related articles for article (PubMed ID: 1440525)
1. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model.
Diness V; Bregengaard C; Erhardtsen E; Hedner U
Thromb Res; 1992 Jul; 67(2):233-41. PubMed ID: 1440525
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model.
Hedner U; Ljundberg J; Lund-Hansen T
Blood Coagul Fibrinolysis; 1990 Jun; 1(2):145-51. PubMed ID: 2130926
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
4. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
Livnat T; Martinowitz U; Zivelin A; Seligsohn U
Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162
[TBL] [Abstract][Full Text] [Related]
5. Effect of hemodilution on coagulation and recombinant factor VIIa efficacy in human blood in vitro.
Darlington DN; Delgado AV; Kheirabadi BS; Fedyk CG; Scherer MR; Pusateri AE; Wade CE; Cap AP; Holcomb JB; Dubick MA
J Trauma; 2011 Nov; 71(5):1152-63. PubMed ID: 21610535
[TBL] [Abstract][Full Text] [Related]
6. Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts.
Larsen OH; Stentoft J; Radia D; Ingerslev J; Sørensen B
Br J Haematol; 2013 Jan; 160(2):228-36. PubMed ID: 23151086
[TBL] [Abstract][Full Text] [Related]
7. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
Tanaka KA; Taketomi T; Szlam F; Calatzis A; Levy JH
Anesth Analg; 2008 Mar; 106(3):732-8, table of contents. PubMed ID: 18292410
[TBL] [Abstract][Full Text] [Related]
8. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count.
Lisman T; Adelmeijer J; Cauwenberghs S; Van Pampus EC; Heemskerk JW; De Groot PG
J Thromb Haemost; 2005 Apr; 3(4):742-51. PubMed ID: 15842358
[TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats.
Diness V; Lund-Hansen T; Hedner U
Thromb Res; 1990 Sep; 59(6):921-9. PubMed ID: 2264019
[TBL] [Abstract][Full Text] [Related]
11. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
Gerotziafas GT; Chakroun T; Depasse F; Arzoglou P; Samama MM; Elalamy I
Thromb Haemost; 2004 May; 91(5):977-85. PubMed ID: 15116259
[TBL] [Abstract][Full Text] [Related]
12. Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa.
Wegert W; Harder S; Bassus S; Kirchmaier CM
Platelets; 2005 Feb; 16(1):45-50. PubMed ID: 15763896
[TBL] [Abstract][Full Text] [Related]
13. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Elg M; Carlsson S; Gustafsson D
Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
[TBL] [Abstract][Full Text] [Related]
14. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor.
Telgt DS; Macik BG; McCord DM; Monroe DM; Roberts HR
Thromb Res; 1989 Dec; 56(5):603-9. PubMed ID: 2626745
[TBL] [Abstract][Full Text] [Related]
15. Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model.
Holst J; Kristensen AT; Kristensen HI; Ezban M; Hedner U
Eur J Vasc Endovasc Surg; 1998 Jun; 15(6):515-20. PubMed ID: 9659887
[TBL] [Abstract][Full Text] [Related]
16. Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study.
Godier A; Mazoyer E; Cymbalista F; Cupa M; Samama CM
J Thromb Haemost; 2007 Feb; 5(2):244-9. PubMed ID: 17129221
[TBL] [Abstract][Full Text] [Related]
17. Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery.
Rao VK; Lobato RL; Bartlett B; Klanjac M; Mora-Mangano CT; Soran PD; Oakes DA; Hill CC; van der Starre PJ
J Cardiothorac Vasc Anesth; 2014 Oct; 28(5):1221-6. PubMed ID: 25281040
[TBL] [Abstract][Full Text] [Related]
18. Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma.
Johansen PB; Bjørn SE; Agersø H; Thorup I; Hermit MB; Sørensen B; Stennicke HR; Ezban M; Tranholm M
Thromb Haemost; 2010 Jul; 104(1):157-64. PubMed ID: 20390231
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models.
Ghosh S; Krege W; Doerr B; Mischnik M; Pragst I; Dickneite G; Herzog E
PLoS One; 2021; 16(10):e0258192. PubMed ID: 34614035
[TBL] [Abstract][Full Text] [Related]
20. Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.
Tatoulis J; Theodore S; Meswani M; Wynne R; Hon-Yap C; Powar N
Interact Cardiovasc Thorac Surg; 2009 Sep; 9(3):459-62. PubMed ID: 19542087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
